Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2984841 | 0.92 | LMNA (0.48) | ATF4LMNASMN1; SMN2HPGDMAPK1 | |
| SCHEMBL2985870 | 0.91 | ATF4 (0.59) | ATF4LMNASMN1; SMN2HPGDMAPK1 | |
| SCHEMBL2981361 | 0.89 | ATF4 (0.57) | ATF4LMNASMN1; SMN2HPGDMAPK1 | |
| SCHEMBL2987483 | 0.87 | ATF4 (0.61) | ATF4LMNASMN1; SMN2HPGDMAPK1 | |
| SCHEMBL2978761 | 0.86 | ATF4 (0.65) | ATF4LMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL2987316 | 0.85 | POLB (0.50) | ATF4LMNASMN1; SMN2HPGDMAPK1 | |
| SCHEMBL2974336 | 0.84 | MEN1 (0.46) | HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL2977860 | 0.84 | ATF4 (0.60) | ATF4LMNASMN1; SMN2HPGDKMT2A | |
| SCHEMBL2981298 | 0.83 | ATF4 (0.56) | ATF4LMNASMN1; SMN2HPGDKMT2A | |
| SCHEMBL16143777 | 0.82 | MAPT (0.44) | LMNAHPGDKMT2ARAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786328-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2010-08-31 | — | — | US | claimed |
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-12-06 | — | — | US | claimed |
| US-7786328-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2010-08-31 | — | — | US | disclosed |
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | DPYD, PKD1, AOC1 | ATF4 1845/4885LMNA 1459/4885SMN1; SMN2 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.